Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In MCL, venetoclax has shown pr...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 108; no. 3; pp. 797 - 810
Main Authors:	Thus, Yvonne J., De Rooij, Martin F.M., Swier, Nathalie, Beijersbergen, Roderick L., Guikema, Jeroen E.J., Kersten, Marie-José, Eldering, Eric, Pals, Steven T., Kater, Arnon P., Spaargaren, Marcel
Format:	Journal Article
Language:	English
Published:	Italy Fondazione Ferrata Storti 01.03.2023 Ferrata Storti Foundation
Subjects:	Adult Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Casein Kinase II - genetics Casein Kinase II - metabolism Cell Line, Tumor Down-Regulation Humans Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - genetics Lymphoma, Mantle-Cell - metabolism Myeloid Cell Leukemia Sequence 1 Protein - metabolism Non-Hodgkin Lymphoma Proto-Oncogene Proteins c-bcl-2
ISSN:	0390-6078, 1592-8721, 1592-8721
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!